Perceptions of psychiatrists toward long-acting injectable antipsychotics: A cross-sectional survey from Fujian, China
5 affiliations
- 1Department of Pharmacy, Xiamen Xianyue Hospital, Xiamen, China.
- 2Xianyue Hospital Affiliated with Xiamen Medical College, Xiamen, China.
- 3Fujian Psychiatric Center, Xiamen, China.
- 4Fujian Clinical Research Center for Mental Disorders, Xiamen, China.
- 5Department of Psychiatry, Xiamen Xianyue Hospital, Xiamen, China.
Abstract
Objective: This study aimed to assess the knowledge, attitudes, and willingness of psychiatrists to promote long-acting injectable antipsychotics (LAIs) in Fujian Province, China, and to identify the influencing factors. Methods: A cross-sectional survey was conducted using convenience sampling among psychiatrists attending a provincial conference. An 18-item online questionnaire was distributed via Wenjuanxing. Descriptive statistics, Mann-Whitney U tests and Spearman’s rank correlation were used. Benjamini-Hochberg FDR correction was applied for multiple correlations Results: A total of 222 psychiatrists completed the survey, with 90 respondents (40.5%) identifying as female. The largest age group was 30–39 years (46.9%). Most participants (51.4%) had > 10 years of clinical experience, and 65 (29.3%) held senior professional titles. Most participants reported adequate knowledge of LAIs (96.4%), recognized their therapeutic value (80.2%) and favorable application prospects (87.8%), and expressed a willingness to promote LAIs (82.4%).High cost was identified as the primary barrier to clinical use (90.5%) and the most critical factor for wider adoption (88.3%). Psychiatrists with more clinical experience (>10 years) held significantly more positive attitudes regarding overall therapeutic value, willingness to promote LAIs, and support for early application (all P < 0.05). Spearman’s correlation analysis indicated that positive attitudes were significantly associated with greater clinical experience (ρ = 0.302, q < 0.01) and higher levels of knowledge (ρ = 0.297, q < 0.01) after FDR correction. Conclusion: Psychiatrists in Fujian Province demonstrated adequate knowledge and generally positive attitudes toward LAIs. Psychiatrists’ willingness to promote LAIs was associated with knowledge level and clinical experience, but reducing the cost of drug patents may contribute to improving the prescription rates. Future efforts should focus on systematic training, academic communication, positive prescribing experiences, and policy coordination to overcome cost and stigma barriers.
Related
- Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal ® ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)
- Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone
- “The injection gives freedom” - An exploration of long-acting injectable HIV treatment acceptance among patients seeking care in two Nairobi tertiary hospitals
- Learner perceptions of AI-mediated affective support in L2 English learning: A cross-sectional survey
- Stakeholder perceptions of antimicrobial resistance governance in livestock production: a cross-sectional study from North-Central Nigeria.
BibTeX
@article{zhou2026perceptions,
title = {{Perceptions of psychiatrists toward long-acting injectable antipsychotics: A cross-sectional survey from Fujian, China}},
author = {Yixiang Zhou and Weijun Gu and Zhiqiang Cui and Yinghua Huang},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0362055},
url = {https://doi.org/10.1371/journal.pone.0362055},
note = {CC BY},
}
RIS
TY - JOUR
TI - Perceptions of psychiatrists toward long-acting injectable antipsychotics: A cross-sectional survey from Fujian, China
AU - Yixiang Zhou
AU - Weijun Gu
AU - Zhiqiang Cui
AU - Yinghua Huang
PY - 2026
DA - 2026/11/02
JO - PLOS One
DO - 10.1371/journal.pone.0362055
UR - https://doi.org/10.1371/journal.pone.0362055
AB - Objective: This study aimed to assess the knowledge, attitudes, and willingness of psychiatrists to promote long-acting injectable antipsychotics (LAIs) in Fujian Province, China, and to identify the influencing factors. Methods: A cross-sectional survey was conducted using convenience sampling among psychiatrists attending a provincial conference. An 18-item online questionnaire was distributed via Wenjuanxing. Descriptive statistics, Mann-Whitney U tests and Spearman’s rank correlation were used. Benjamini-Hochberg FDR correction was applied for multiple correlations Results: A total of 222 psychiatrists completed the survey, with 90 respondents (40.5%) identifying as female. The largest age group was 30–39 years (46.9%). Most participants (51.4%) had > 10 years of clinical experience, and 65 (29.3%) held senior professional titles. Most participants reported adequate knowledge of LAIs (96.4%), recognized their therapeutic value (80.2%) and favorable application prospects (87.8%), and expressed a willingness to promote LAIs (82.4%).High cost was identified as the primary barrier to clinical use (90.5%) and the most critical factor for wider adoption (88.3%). Psychiatrists with more clinical experience (>10 years) held significantly more positive attitudes regarding overall therapeutic value, willingness to promote LAIs, and support for early application (all P < 0.05). Spearman’s correlation analysis indicated that positive attitudes were significantly associated with greater clinical experience (ρ = 0.302, q < 0.01) and higher levels of knowledge (ρ = 0.297, q < 0.01) after FDR correction. Conclusion: Psychiatrists in Fujian Province demonstrated adequate knowledge and generally positive attitudes toward LAIs. Psychiatrists’ willingness to promote LAIs was associated with knowledge level and clinical experience, but reducing the cost of drug patents may contribute to improving the prescription rates. Future efforts should focus on systematic training, academic communication, positive prescribing experiences, and policy coordination to overcome cost and stigma barriers.
SN - 1932-6203
ER -